Cardiff Oncology (CRDF) Competitors $2.94 +0.15 (+5.38%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.02 +0.09 (+2.89%) As of 04/15/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. GYRE, DAWN, AVXL, PHVS, XERS, NTLA, EOLS, AVDL, CRON, and PRAXShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Xeris Biopharma (XERS), Intellia Therapeutics (NTLA), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Gyre Therapeutics Day One Biopharmaceuticals Anavex Life Sciences Pharvaris Xeris Biopharma Intellia Therapeutics Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Gyre Therapeutics (NASDAQ:GYRE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Is GYRE or CRDF more profitable? Gyre Therapeutics has a net margin of -84.57% compared to Cardiff Oncology's net margin of -6,238.17%. Cardiff Oncology's return on equity of -73.97% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Cardiff Oncology -6,238.17%-73.97%-60.40% Do institutionals and insiders believe in GYRE or CRDF? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor GYRE or CRDF? Cardiff Oncology received 41 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 64.62% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesCardiff OncologyOutperform Votes4264.62% Underperform Votes2335.38% Which has higher valuation and earnings, GYRE or CRDF? Cardiff Oncology has lower revenue, but higher earnings than Gyre Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M7.44-$92.93M$0.05168.00Cardiff Oncology$683K286.36-$41.44M-$0.94-3.13 Which has more risk & volatility, GYRE or CRDF? Gyre Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Does the media prefer GYRE or CRDF? In the previous week, Gyre Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Gyre Therapeutics and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.47 beat Gyre Therapeutics' score of 0.28 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer GYRE or CRDF? Cardiff Oncology has a consensus target price of $11.67, indicating a potential upside of 296.83%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGyre Therapeutics beats Cardiff Oncology on 9 of the 17 factors compared between the two stocks. Remove Ads Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.58M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-3.1331.0021.7317.81Price / Sales286.36441.17379.2094.61Price / CashN/A168.6838.1534.64Price / Book1.883.476.464.00Net Income-$41.44M-$72.06M$3.20B$247.23M7 Day Performance15.29%9.33%6.54%7.26%1 Month Performance-26.50%-16.97%-8.55%-6.26%1 Year Performance-44.32%-29.10%10.33%-0.18% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.1693 of 5 stars$2.94+5.4%$11.67+296.8%-44.3%$195.58M$683,000.00-3.1320News CoverageGYREGyre Therapeutics0.1333 of 5 stars$7.62+10.1%N/A-49.0%$713.32M$105.76M152.4040Short Interest ↑High Trading VolumeDAWNDay One Biopharmaceuticals2.4554 of 5 stars$7.02-2.8%$32.29+359.9%-48.1%$711.51M$131.16M-6.8260Gap DownAVXLAnavex Life Sciences3.5111 of 5 stars$8.33+1.7%$44.00+428.2%+115.6%$708.58MN/A-15.1540Positive NewsPHVSPharvaris1.4049 of 5 stars$13.21-7.5%$40.50+206.6%-30.8%$690.75MN/A-4.7230XERSXeris Biopharma4.319 of 5 stars$4.41flat$6.10+38.3%+136.8%$678.88M$203.07M-9.80290Short Interest ↑News CoveragePositive NewsGap DownHigh Trading VolumeNTLAIntellia Therapeutics4.3268 of 5 stars$6.54-1.4%$37.56+474.2%-67.9%$677.00M$57.88M-1.20600Gap DownHigh Trading VolumeEOLSEvolus3.4956 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2544 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionNews CoverageGap DownCRONCronos Group1.5759 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9287 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110 Remove Ads Related Companies and Tools Related Companies GYRE Competitors DAWN Competitors AVXL Competitors PHVS Competitors XERS Competitors NTLA Competitors EOLS Competitors AVDL Competitors CRON Competitors PRAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDF Stock Free CRDF Stock Alerts